Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer

被引:29
作者
Guney, Nese [1 ]
Soydinc, Hilal Oguz [1 ]
Derin, Duygu [1 ]
Tas, Faruk [1 ]
Camlica, Hakan [1 ]
Duranyildiz, Derya [1 ]
Yasasever, Vildan [1 ]
Topuz, Erkan [1 ]
机构
[1] Istanbul Univ, Inst Oncol, TR-34390 Istanbul, Turkey
关键词
cell adhesion molecules; ICAM-1; E-selectin; lung cancer;
D O I
10.1007/s12032-007-9026-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell adhesion is a basic count in inter- and intra-cellular communication and plays an important role in tumor progression. This study was conducted to investigate the serum levels of intercellular adhesion molecule (ICAM-1) and E-selectin in patients with advanced stage non-small cell lung cancer (NSCLC) and the relationships with known prognostic parameters and therapy. These serum factors were measured of 57 NSCLC patients pathologically verified before and after chemotherapy in comparison with 24 healthy controls by using ELISA method. Serum levels of ICAM-1 were increased significantly in NSCLC patients compared with the healthy controls (P = 0.006). However, serum E-selectin levels were not significantly different from healthy control groups (0.643). No statistically significant relationships were found between investigated all serum parameters and various characteristics of patients, and the diseases such as stage and tumor burden. Likewise, we also found no correlation between serum ICAM-1 and E-selectin (P = 0.78). We found that serum ICAM-1 levels were decreased owing to the chemotherapy effect, independently from chemotherapy response. However, serum E-selectin levels were not changed by the chemotherapy effect. The median survival of all patients was 11.9 months and 1-year survival rate was 47.6%. We found that patients performance status (P = 0.013), age (P = 0.015), and weight loss (P = 0.007) were prognostic factors for survival. Serum E-selectin levels showed a trend (P = 0.08) related to worse prognosis, however serum ICAM-1 levels were determined as ineffective on survival (P = 0.11). Multivariate analysis revealed that only weight loss (P = 0.005) and E-selectin levels (P = 0.002) remained as an independent prognostic factor for survival in patients with advanced NSCLC. In conclusion, our data suggest that higher serum ICAM-1 can be useful for diagnosis while E-selectin levels have prognostic significance and could be a potential prognostic factor in NSCLC patients.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 38 条
[1]   Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery [J].
Alexiou, D ;
Karayiannakis, AJ ;
Syrigos, KN ;
Zbar, A ;
Kremmyda, A ;
Bramis, I ;
Tsigris, C .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) :2392-2397
[2]   Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer [J].
Aljada, IS ;
Ramnath, N ;
Donohue, K ;
Harvey, S ;
Brooks, JJ ;
Wiseman, SM ;
Khoury, T ;
Loewen, G ;
Slocum, HK ;
Anderson, TM ;
Bepler, G ;
Tan, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3218-3229
[3]   CIRCULATING INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1), E-SELECTIN AND VASCULAR CELL-ADHESION MOLECULE-1 (VCAM-1) IN HUMAN MALIGNANCIES [J].
BANKS, RE ;
GEARING, AJH ;
HEMINGWAY, IK ;
NORFOLK, DR ;
PERREN, TJ ;
SELBY, PJ .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :122-124
[4]   SELECTINS [J].
BEVILACQUA, MP ;
NELSON, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (02) :379-387
[5]   Redirection of tumor metastasis by expression of E-selectin in vivo [J].
Biancone, L ;
Araki, M ;
Araki, K ;
Vassalli, P ;
Stamenkovic, I .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :581-587
[6]  
CARLOS TM, 1994, BLOOD, V84, P2068
[7]  
DEJANA E, 1992, LAB INVEST, V66, P324
[8]   To stick or not to stick: The new leukocyte homing paradigm [J].
Dunon, D ;
Piali, L ;
Imhof, BA .
CURRENT OPINION IN CELL BIOLOGY, 1996, 8 (05) :714-723
[9]   Novel targets for lung cancer therapy: Part II [J].
Dy, GK ;
Adjei, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :3016-3028
[10]  
Esposito V, 2002, ANTICANCER RES, V22, P4039